Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours
NCT ID: NCT02853422
Last Updated: 2020-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
199 participants
OBSERVATIONAL
2016-04-30
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient able to read and understand the study questionnaires.
* Patient who has given informed consent in writing to take part in the study.
Exclusion Criteria
* Patients with another serious malignancy.
* Patients unable to meet the requirements of the protocol (non-compliant patients or those unfit to answer the questionnaires).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Portuguès de Oncologia de Lisboa
Lisbon, , Portugal
Instituto Portuguès de Oncologia do Porto
Porto, , Portugal
Hospital General Univ. Elche
Alicante, , Spain
Hospital Clinico y Provincial
Barcelona, , Spain
Hospital Univ. Burgos
Burgos, , Spain
Hospital Jerez de la Frontera
Cadiz, , Spain
Hospital San Pedro de Alcántara
Cáceres, , Spain
Hospital General Univ. Ciudad Real
Ciudad Real, , Spain
Hospital Univ. de Cabueñes
Gijón, , Spain
ICO Girona
Girona, , Spain
Hospital Can Mises
Ibiza Town, , Spain
Hospital Univ. León
León, , Spain
Hospital de La Princesa
Madrid, , Spain
Hospital Gregorio Marañón
Madrid, , Spain
Hospital Univ. Ramón y Cajal
Madrid, , Spain
Hospital Clínico San Carlos
Madrid, , Spain
Hospital Univ. Puerta del Hierro
Madrid, , Spain
Hospital Regional Univ. Málaga
Málaga, , Spain
Hospital Univ.Virgen de la Victoria
Málaga, , Spain
Hospital Rey Juan Carlos I
Móstoles, , Spain
Hospital General Univ. Morales Meseguer
Murcia, , Spain
Hospital Univ. Son Espases
Palma, , Spain
Hospital Son Llàtzer
Palma, , Spain
Complejo Hospitalario de Navarra
Pamplona, , Spain
Hospital Clínico Univ. Salamanca
Salamanca, , Spain
Hospital Clínico Univ. de Santiago
Santiago de Compostela, , Spain
Hospital General de Segovia
Segovia, , Spain
Hospital Univ. Virgen del Rocío
Seville, , Spain
Hospital Univ. Mútua de Terrasa
Terrassa, , Spain
Hospital de Galdakao
Usansolo, , Spain
Hospital Univ. Fe
Valencia, , Spain
Hospital Clínico Univ. Valladolid
Valladolid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IPS-ANT- 2015-01
Identifier Type: OTHER
Identifier Source: secondary_id
A-ES-52030-351
Identifier Type: -
Identifier Source: org_study_id